The United States Food and Drug Administration approved the newest Type 2 Diabetes drug called Trulicity. It can help lower down blood sugar even if it is given just once a week. Diabetes is a common lifestyle illness affecting more and more people every year.
In fact, there are about 347 million people who are suffering from Diabetes in the whole world. In the United States alone, there are 26 million Americans with Diabetes. In the date stated, about 90% has type 2 Diabetes. High blood sugar has many complications if left unattended and uncontrolled. Complications include heart problems, blindness, nerve damage and even kidney disease.
The drug is a type of drug under the group glucagon-like peptide-1 (GLP-1) receptor agonist. The generic name of it is dulaglutide while the brand name is Trulicity. The FDA says that before they approved the release of the drug, they evaluated it through six clinical trials. They tested it on 3,342persons who were diagnosed with Diabetes Type 2. Furthermore, they were not studied while taking in other drugs to lower their blood sugar. The results revealed that when the patients were being injected with the weekly drug Trulicity, they had good results and improvements in their blood sugar levels.
It is injected subcutaneously just like the previous insulin injections. There are also common side effects associated with the administration of the medicine including nausea and vomiting. However, the drug is believed to be associated with thyroid tumors because of their effects on rodents.
The FDA warns that the medicine should be prescribed to patients with a history of thyroid cancer or those with endocrine neoplasia syndrome. The drug wsa manufactured by Eli Lilly and Company. It is not recommended for patients with Type 1 Diabetes Mellitus. Furthermore, the FDA is recommending that the company conduct a post-marketing study to determine if there are any cardiovascular issues on people using the drug.